HIVHITSNCT03757104
Home-based Intervention to Test and Start
A study testing micro-incentive, EPIC-HIV and micro-incentive and EPIC-HIV in people with HIV and HIV Testing, run by Africa Health Research Institute at 1 site in South Africa.
Trial summary
This study aims to establish the causal impact of two interventions - micro-incentives and a male-sensitive HIV- specific decision support app - on population-level HIV viral load and HIV-related mortality in men, as well as on population-based HIV incidence in young women. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- Conditions the study is for
- HIV, HIV Testing, Linkage to Care
- What is being tested?
- micro-incentive, EPIC-HIV and micro-incentive and EPIC-HIV
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,667 participants
- Where
- 1 siteSouth Africa
- Study dates
- 6 Feb 2018to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- 15 years old and above
- Resident members of households within the Population Intervention Platform
- Have consented to participate in Population Intervention Platform
- additional eligibility criteria for EPIC-HIV
- -Male
Who cannot join
- Refused to take part in Population Intervention Platform
- Participant reported to already be on ART
Trial locations and contacts
1 site in 1 country.
South Africa1 site, 1 recruiting
- Recruiting
AHRI
Mtubatuba, KwaZulu-Natal, 3935
Frank Tanser, PhD
About this study
Official title: Home-based Interventions to Test and Start (HITS): a Cluster-randomized Controlled Trial to Reduce Mortality and Incidence Through HIV Treatment
This study aims to establish the causal impact of two interventions - micro-incentives and a male-sensitive HIV- specific decision support app - on population-level HIV viral load and HIV-related mortality in men, as well as on population-based HIV incidence in young women.
Read the detailed description
Research aim:
The primary aim of the home-based intervention to test and start (HITS) trial is to establish whether (i) the provision of two micro-incentives and (ii) a male-sensitive and HIV-specific decision support app will reduce population-level HIV viral load and HIV-related mortality in men, as well as population-level HIV incidence in young women.
Specific objectives
- Establish the causal impact of two micro-incentives (aimed at increasing uptake of home-based HIV testing and linkage to care, respectively) on:
- Population-level HIV viral load in men
- Population-level HIV-related mortality in men
- Population-level HIV incidence in young women.
- Establish the causal impact of a male-sensitive and HIV-specific decision- support app (called EPIC-HIV) on:
- Population-level HIV viral load in men
- Population-level HIV-related mortality in men
- Population-level HIV incidence in young women.
- Establish the causal impact of the two conditional micro-incentives on:
- HIV status knowledge in men and women
- HIV knowledge in men and women
- HIV treatment knowledge in men and women
- HIV treatment utilization in men and women
- Sexual behavior in men and women
- Healthcare utilization in men and women
- Household healthcare expenditures
- Household wealth
- Retention in HIV care in men and women
- Establish the causal impact of the male-sensitive HIV-specific decision support app on:
- HIV status knowledge in men and women
- HIV knowledge in men and women
- HIV treatment knowledge in men and women
- HIV treatment utilization in men and women
- Sexual behavior in men and women
- Healthcare utilization in men and women
- Household healthcare expenditures
- Household wealth
- Retention in HIV care in men and women
Hypothesis:
The investigators hypothesize that each of the two interventions - micro-incentives aimed at encouraging HIV testing and linkage to HIV care and a male-sensitive HIV-specific decision support app - will each increase HIV testing and HIV treatment uptake and via this mechanism lead to reduced population viral load and HIV-related mortality particularly in men. Reduced viral load among men, in turn, will reduce HIV incidence in young women.
Research design Following a formative phase to develop the design of the two HITS intervention the investigators will determine the causal impact of the interventions on our three primary endpoints in a 2x2 factorial cluster-randomized controlled trial with a baseline adjustment. A mixed- methods approach will be employed that combines the strengths of rapid formative social science research (that will inform the precise delivery of the HITS intervention) with a causally rigorous statistical methodology to evaluate the effectiveness of the HITS intervention.
The HITS intervention will be delivered through the Africa Health Research Institute's (AHRI) existing HIV surveillance operations. The investigators will randomize 45 communities to the four interventions. 8 communities each will receive one of the interventions (micro-incentives only, male-sensitive HIV-specific decision support app only); 8 communities will receive both interventions and 21 communities will receive standard-of-care. Communities will be stratified by incidence in young women (2004-2016) to derive a similar baseline incidence across intervention and standard-of-care communities prior to the implementation of the intervention. Both men and women will be eligible to receive the financial incentives to test and link to care, whilst only men will be eligible for the EPIC HIV-specific decision support application.
In the total of 3x8=24 communities in the intervention arms, an estimated total of 4,667 individuals will receive a HITS intervention. In the 21 communities, 4,900 individuals will receive the standard-of-care. Outcomes will be assessed in all eligible individuals living in the 45 communities, which together have an estimated population size of 30,000 adults.
Sample size calculation The study was powered using the outcome of HIV incidence in women aged 15-30. Using actual Africa Health Research Institute HIV incidence data, the investigators simulated the HITS intervention introduced in 2011 to 24 of the 45 communities in the study area. The investigators simulated an intervention that led to a 25% reduction in arm 1 (micro-incentives), 25% reduction in arm 2 (male-sensitive counselling) and a 32% reduction in the combined arm. Communities were stratified by baseline incidence (three strata) in young women (2004-2011) to allow for a similar baseline incidence in intervention and control communities and the investigators included a random effect in the simulations to adjust for clustering by community. The results show that the investigators would have been able to detect this reduction in incidence in >80% of simulation replicates (p<0.05). Therefore, if the investigators were to introduce the HITS intervention in 2018 and follow young women up for at least 3 years post intervention (ie utilize a total of 17 years of incidence data - 2004 to 2021) the investigators would be in excess of 90% powered to detect such a reduction in incidence in this critical age-group.
Research methodology Research site:
The trial will be managed from the Africa Health Research Institute, formerly Africa Centre that conducts a large longitudinal Demographic and Health surveillance. Participants will be enrolled during the routine HIV surveillance study (Population Intervention Program) - trained fieldworkers visit participants at home once a year to conduct household surveys using tablet computers and offer point of care HIV testing to all individuals aged 15+.
Study procedures:
In those arms of this cluster Randomized Controlled Trial (RCT) that include the once-off two-stage micro-incentive scheme, consenting men and women will be offered a first opportunity to earn a R50 food voucher (redeemable in a local supermarket) conditional on HIV testing. If a participant tests positive for HIV, he/she will have the opportunity to receive a second R50 food voucher conditional on linking within 6 weeks following the HIV test to one of the 11 local primary care clinics where HIV treatment and care are available.
In those arms of this cluster RCT that include the male-sensitive HIV-specific decision support app, men will be offered EPIC-HIV (a first version, so-called EPIC-HIV-1) prior HIV counseling and testing. EPIC-HIV-1 is aimed at increasing HIV testing uptake. Those participants who do not link to care within a month of the HIV test will be offered a second version of EPIC-HIV (so-called EPIC-HIV-2) at home to encourage linkage to care.
Follow up of participants:
Participants will be followed up routinely through the AHRI's ongoing population-based HIV surveillance. All participants will be followed up for at least 3 years.
Linkage to care will be routinely established via the AHRI's ongoing linkage of clinical records for all patients in the local public sector ART program in the demographic surveillance.
Data management: Data will be collected and managed by AHRI Research Data Management within PIP databases as per AHRI comprehensive study operating procedures (SOPs). The Population Intervention Platform (PIP) database has strictly restricted access via a data enclave on a secure server.
Data analysis:
All primary analyses (of both primary and secondary endpoints) will be intent-to-treat (ITT).
For the binary primary outcomes - HIV testing uptake, HIV treatment linkage, and population-level HIV viral suppression - the investigators will use generalized linear models with a Poisson distribution, log link function, and robust error terms to determine effect sizes (risk ratios).
For the two survival-analytical primary endpoints - population-level mortality among men and population-level HIV incidence among women - the investigators will use the Cox proportional hazards model to determine effect sizes (hazard ratios). If the proportional hazards assumption of the Cox model is violated, the investigators will use appropriate alternative survival analytical models.
In all primary analyses, the investigators will adjust for both baseline endpoints and clustering. For the survival analytical endpoints, the investigators will use data from the period 2004-2017 for baseline endpoint adjustment.
In addition, to the ITT analyses, the investigators will measure intervention effects adjusted for non-compliance using instrumental variable (IV) approaches
- Conditions
- HIV, HIV Testing, Linkage to Care
- Being tested
- micro-incentive, EPIC-HIV, micro-incentive and EPIC-HIV
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
micro-incentiveBehavioural
Also called Food voucher
Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
EPIC-HIVBehavioural
Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
micro-incentive and EPIC-HIVBehavioural
Also called Food Voucher and EPIC-HIV
micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.
EPIC-HIV 1:
Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
| Study group | Role | What they receive |
|---|---|---|
| micro-incentives | Experimental | micro-incentives only (8 communities) Receives: Behavioral: micro-incentive |
| EPIC-HIV | Experimental | Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities) Receives: Behavioral: EPIC-HIV |
| micro-incentive and EPIC-HIV | Experimental | micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities) Receives: Behavioral: micro-incentive and EPIC-HIV |
| control | No intervention | standard of care |
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV testing uptake at point of test offer in men
% received the rapid HIV test at home among those offered the test in men
Measured: Baseline
HIV treatment linkage at 1 year in men
% who visited study clinics and initiated antiretroviral therapy (ART) in men
Measured: year 1
Population-level HIV viral suppression in men
Change in proportion with detectable viremia in men; HIV testing and viral load measurements are performed on the dried blood spot (DBS) samples collected during the annual survey
Measured: year 1
Population-level HIV-related mortality in men
Change in HIV-related mortality rate measured as the number of HIV-related deaths per 1000 person-years of observation in men
Measured: year 3
Population-level HIV incidence in young women (15-30 years of age)
Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years of follow up) in young women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
Secondary outcomes (26)
HIV testing uptake at point of test offer in women
% received rapid HIV test at home among those offered the test in women
Measured: Baseline
HIV treatment linkage at 1 year in women
% who visited study clinics and initiated ART in women
Measured: year 1
Population-level HIV viral suppression (both sexes)
Change in proportion with detectable viremia in both men and women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 1
Population-level HIV viral suppression (both sexes)
Change in proportion with detectable viremia in both men and women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
Population-level HIV viral suppression in women
Change in proportion with detectable viremia in women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 1
Population-level HIV viral suppression in women
Change in proportion with detectable viremia in women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
Population-level HIV viral suppression in men
Change in proportion with detectable viremia in men; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
Population level HIV incidence (both sexes)
Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years of follow up) in both men and women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
Population-level HIV-related mortality (both sexes)
Change in HIV-related mortality rate measured as the number of HIV-related deaths per 1000 person-years of observation in both men and women
Measured: year 3
Population-level all-cause mortality (both sexes)
Change in all-cause mortality rate measured as the number of all-cause deaths per 1000 person-years of observation in both men and women
Measured: year 3
Population-level HIV-related mortality in women
Change in HIV-related mortality rate measured as the number of HIV-related deaths per 1000 person-years of observation in women
Measured: year 3
Population-level HIV incidence in men
Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years of follow up) in men; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
Measured: year 3
HIV status knowledge in men and women
% ever received a test result for HIV in men and women
Measured: year 1
HIV prevention knowledge in men and women
% reporting ever hearing about pre-exposure prophylaxis (PrEP)
Measured: year 1
HIV treatment utilization in men and women
% reporting ever taking up ART for own health in men and women
Measured: year 1
Reported condom use in men and women
% reporting condom use at last sex in men and women
Measured: year 1
Tuberculosis (TB) healthcare utilization in men and women
% reported starting TB treatment in the past 12 months in men and women
Measured: year 1
Diabetes Healthcare utilization in men and women
% reported starting diabetes treatment in the past 12 months
Measured: year 1
Hypertension healthcare utilization in men and women
% reported starting blood pressure treatment in the past 12 months in men and women
Measured: year 1
Household wealth (household assets)
Number of household assets (selected from a predefined list of 32 assets)
Measured: year 3
Household wealth (food security)
% of adults in the household ever cutting the size of meals or missing meals due to insufficient money for food in the past 12 months
Measured: year 3
Partnership patterns in men and women
% reporting having more than one sexual partner in the past 12 months in men and women
Measured: year 1
Retention in HIV care in men and women
% who are retained in care (% patients having an ART clinic visit in previous 3 months) at 1 year post-initiation in men and women
Measured: year 1
Retention in HIV care in men and women
% who are retained in care (% patients having an ART clinic visit in previous 3 months) at 3 years post-initiation in men and women
Measured: year 3
Patient viral suppression in men and women
% who are remain virally suppressed (% patients where virus is undetectable) 1 year post-initiation in men and women
Measured: year 1
Patient viral suppression in men and women
% who are remain virally suppressed (% patients where virus is undetectable) 3-years post-initiation in men and women
Measured: year 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2018
- Study start6 Feb 2018
- Primary completion31 Dec 2021 (estimated)
- Study completion31 Dec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 4,667 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Africa Health Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Heidelberg University, University College, London, London School of Hygiene and Tropical Medicine, University of Glasgow, University of Southampton
- Responsible party
- Principal investigator, Frank, Africa Health Research Institute
- Investigators
- Frank Tanser, PhD, Principal investigator, Africa Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03757104
- Sponsor's protocol ID
- A0001-BFC398/16
- Acronym
- HITS
- Status last verified
- Nov 2018
- First submitted
- 31 Oct 2018
- Last updated
- 28 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Barnighausen TW, Tanser F. Evaluating the impact of conditional micro-incentives on linkage to HIV care in rural South Africa: results from the Home-Based Intervention to Test and Start (HITS) trial. Health Policy Plan. 2026 Oct 19;41(9):1527-1542. doi: 10.1093/heapol/czag088.
PubMed 42446180Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Blandford A, Barnighausen T, Tanser F. Effect of a Male-Targeted Digital Decision Support Application Aimed at Increasing Linkage to HIV Care Among Men: Findings from the HITS Cluster Randomized Clinical Trial in Rural South Africa. AIDS Behav. 2025 Jan;29(1):1-12. doi: 10.1007/s10461-024-04465-1. Epub 2024 Sep 11.
PubMed 39259239Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Barnighausen T, Tanser F. The impact of a conditional financial incentive on linkage to HIV care: Findings from the HITS cluster randomized clinical trial in rural South Africa. medRxiv [Preprint]. 2024 Mar 18:2024.03.15.24304278. doi: 10.1101/2024.03.15.24304278.
PubMed 38562873Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Blandford A, Barnighausen T, Tanser F. Effect of a male-targeted digital decision support application aimed at increasing linkage to HIV care among men: Findings from the HITS cluster randomized clinical trial in rural South Africa. medRxiv [Preprint]. 2024 Mar 18:2024.03.15.24304373. doi: 10.1101/2024.03.15.24304373.
PubMed 38562824Makofane K, Kim HY, Tchetgen Tchetgen E, Bassett MT, Berkman L, Adeagbo O, McGrath N, Seeley J, Shahmanesh M, Yapa HM, Herbst K, Tanser F, Barnighausen T. Impact of family networks on uptake of health interventions: evidence from a community-randomized control trial aimed at increasing HIV testing in South Africa. J Int AIDS Soc. 2023 Aug;26(8):e26142. doi: 10.1002/jia2.26142.
PubMed 37598389Tanser FC, Kim HY, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Sartorius B, Yapa HM, Zuma T, Zeitlin A, Blandford A, Dobra A, Barnighausen T. Home-Based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa. J Int AIDS Soc. 2021 Feb;24(2):e25665. doi: 10.1002/jia2.25665.
PubMed 33586911
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home-based Interventions to Test and Start (HITS): a Cluster-randomized Controlled Trial to Reduce Mortality and Incidence Through HIV Treatment
- ClinicalTrials.gov ID
- NCT03757104
- Acronym / sponsor ID
- HITS / A0001-BFC398/16
- Conditions
- HIV, HIV Testing, Linkage to Care
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 4,667 participants (estimated)
- Lead sponsor
- Africa Health Research InstituteUniversity, hospital or other
- Collaborators
- Heidelberg University, University College, London, London School of Hygiene and Tropical Medicine, University of Glasgow, University of Southampton
- Study start
- 6 Feb 2018 (actual)
- Primary completion
- 31 Dec 2021 (estimated)
- Study completion
- 31 Dec 2022 (estimated)
- First posted
- 28 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to establish the causal impact of two interventions - micro-incentives and a male-sensitive HIV- specific decision support app - on population-level HIV viral load and HIV-related mortality in men, as well as on population-based HIV incidence in young women.
Detailed description
Research aim:
The primary aim of the home-based intervention to test and start (HITS) trial is to establish whether (i) the provision of two micro-incentives and (ii) a male-sensitive and HIV-specific decision support app will reduce population-level HIV viral load and HIV-related mortality in men, as well as population-level HIV incidence in young women.
Specific objectives
- Establish the causal impact of two micro-incentives (aimed at increasing uptake of home-based HIV testing and linkage to care, respectively) on:
- Population-level HIV viral load in men
- Population-level HIV-related mortality in men
- Population-level HIV incidence in young women.
- Establish the causal impact of a male-sensitive and HIV-specific decision- support app (called EPIC-HIV) on:
- Population-level HIV viral load in men
- Population-level HIV-related mortality in men
- Population-level HIV incidence in young women.
- Establish the causal impact of the two conditional micro-incentives on:
- HIV status knowledge in men and women
- HIV knowledge in men and women
- HIV treatment knowledge in men and women
- HIV treatment utilization in men and women
- Sexual behavior in men and women
- Healthcare utilization in men and women
- Household healthcare expenditures
- Household wealth
- Retention in HIV care in men and women
- Establish the causal impact of the male-sensitive HIV-specific decision support app on:
- HIV status knowledge in men and women
- HIV knowledge in men and women
- HIV treatment knowledge in men and women
- HIV treatment utilization in men and women
- Sexual behavior in men and women
- Healthcare utilization in men and women
- Household healthcare expenditures
- Household wealth
- Retention in HIV care in men and women
Hypothesis:
The investigators hypothesize that each of the two interventions - micro-incentives aimed at encouraging HIV testing and linkage to HIV care and a male-sensitive HIV-specific decision support app - will each increase HIV testing and HIV treatment uptake and via this mechanism lead to reduced population viral load and HIV-related mortality particularly in men. Reduced viral load among men, in turn, will reduce HIV incidence in young women.
Research design Following a formative phase to develop the design of the two HITS intervention the investigators will determine the causal impact of the interventions on our three primary endpoints in a 2x2 factorial cluster-randomized controlled trial with a baseline adjustment. A mixed- methods approach will be employed that combines the strengths of rapid formative social science research (that will inform the precise delivery of the HITS intervention) with a causally rigorous statistical methodology to evaluate the effectiveness of the HITS intervention.
The HITS intervention will be delivered through the Africa Health Research Institute's (AHRI) existing HIV surveillance operations. The investigators will randomize 45 communities to the four interventions. 8 communities each will receive one of the interventions (micro-incentives only, male-sensitive HIV-specific decision support app only); 8 communities will receive both interventions and 21 communities will receive standard-of-care. Communities will be stratified by incidence in young women (2004-2016) to derive a similar baseline incidence across intervention and standard-of-care communities prior to the implementation of the intervention. Both men and women will be eligible to receive the financial incentives to test and link to care, whilst only men will be eligible for the EPIC HIV-specific decision support application.
In the total of 3x8=24 communities in the intervention arms, an estimated total of 4,667 individuals will receive a HITS intervention. In the 21 communities, 4,900 individuals will receive the standard-of-care. Outcomes will be assessed in all eligible individuals living in the 45 communities, which together have an estimated population size of 30,000 adults.
Sample size calculation The study was powered using the outcome of HIV incidence in women aged 15-30. Using actual Africa Health Research Institute HIV incidence data, the investigators simulated the HITS intervention introduced in 2011 to 24 of the 45 communities in the study area. The investigators simulated an intervention that led to a 25% reduction in arm 1 (micro-incentives), 25% reduction in arm 2 (male-sensitive counselling) and a 32% reduction in the combined arm. Communities were stratified by baseline incidence (three strata) in young women (2004-2011) to allow for a similar baseline incidence in intervention and control communities and the investigators included a random effect in the simulations to adjust for clustering by community. The results show that the investigators would have been able to detect this reduction in incidence in >80% of simulation replicates (p<0.05). Therefore, if the investigators were to introduce the HITS intervention in 2018 and follow young women up for at least 3 years post intervention (ie utilize a total of 17 years of incidence data - 2004 to 2021) the investigators would be in excess of 90% powered to detect such a reduction in incidence in this critical age-group.
Research methodology Research site:
The trial will be managed from the Africa Health Research Institute, formerly Africa Centre that conducts a large longitudinal Demographic and Health surveillance. Participants will be enrolled during the routine HIV surveillance study (Population Intervention Program) - trained fieldworkers visit participants at home once a year to conduct household surveys using tablet computers and offer point of care HIV testing to all individuals aged 15+.
Study procedures:
In those arms of this cluster Randomized Controlled Trial (RCT) that include the once-off two-stage micro-incentive scheme, consenting men and women will be offered a first opportunity to earn a R50 food voucher (redeemable in a local supermarket) conditional on HIV testing. If a participant tests positive for HIV, he/she will have the opportunity to receive a second R50 food voucher conditional on linking within 6 weeks following the HIV test to one of the 11 local primary care clinics where HIV treatment and care are available.
In those arms of this cluster RCT that include the male-sensitive HIV-specific decision support app, men will be offered EPIC-HIV (a first version, so-called EPIC-HIV-1) prior HIV counseling and testing. EPIC-HIV-1 is aimed at increasing HIV testing uptake. Those participants who do not link to care within a month of the HIV test will be offered a second version of EPIC-HIV (so-called EPIC-HIV-2) at home to encourage linkage to care.
Follow up of participants:
Participants will be followed up routinely through the AHRI's ongoing population-based HIV surveillance. All participants will be followed up for at least 3 years.
Linkage to care will be routinely established via the AHRI's ongoing linkage of clinical records for all patients in the local public sector ART program in the demographic surveillance.
Data management: Data will be collected and managed by AHRI Research Data Management within PIP databases as per AHRI comprehensive study operating procedures (SOPs). The Population Intervention Platform (PIP) database has strictly restricted access via a data enclave on a secure server.
Data analysis:
All primary analyses (of both primary and secondary endpoints) will be intent-to-treat (ITT).
For the binary primary outcomes - HIV testing uptake, HIV treatment linkage, and population-level HIV viral suppression - the investigators will use generalized linear models with a Poisson distribution, log link function, and robust error terms to determine effect sizes (risk ratios).
For the two survival-analytical primary endpoints - population-level mortality among men and population-level HIV incidence among women - the investigators will use the Cox proportional hazards model to determine effect sizes (hazard ratios). If the proportional hazards assumption of the Cox model is violated, the investigators will use appropriate alternative survival analytical models.
In all primary analyses, the investigators will adjust for both baseline endpoints and clustering. For the survival analytical endpoints, the investigators will use data from the period 2004-2017 for baseline endpoint adjustment.
In addition, to the ITT analyses, the investigators will measure intervention effects adjusted for non-compliance using instrumental variable (IV) approaches
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| micro-incentives | Experimental | Behavioral: micro-incentivemicro-incentives only (8 communities) |
| EPIC-HIV | Experimental | Behavioral: EPIC-HIVEmpowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities) |
| micro-incentive and EPIC-HIV | Experimental | Behavioral: micro-incentive and EPIC-HIVmicro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities) |
| control | No intervention | –standard of care |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- 15 years old and above
- Resident members of households within the Population Intervention Platform
- Have consented to participate in Population Intervention Platform
- additional eligibility criteria for EPIC-HIV
- -Male
Key exclusion criteria (2 listed)
- Refused to take part in Population Intervention Platform
- Participant reported to already be on ART
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| micro-incentiveAlso: Food voucherResidents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test | Behavioural | micro-incentives |
| EPIC-HIVMen in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care. | Behavioural | EPIC-HIV |
| micro-incentive and EPIC-HIVAlso: Food Voucher and EPIC-HIVmicro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test. EPIC-HIV 1: Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care. | Behavioural | micro-incentive and EPIC-HIV |
Primary outcome
HIV testing uptake at point of test offer in men
Time frame: Baseline
% received the rapid HIV test at home among those offered the test in men
HIV treatment linkage at 1 year in men
Time frame: year 1
% who visited study clinics and initiated antiretroviral therapy (ART) in men
Population-level HIV viral suppression in men
Time frame: year 1
Change in proportion with detectable viremia in men; HIV testing and viral load measurements are performed on the dried blood spot (DBS) samples collected during the annual survey
Population-level HIV-related mortality in men
Time frame: year 3
Change in HIV-related mortality rate measured as the number of HIV-related deaths per 1000 person-years of observation in men
Population-level HIV incidence in young women (15-30 years of age)
Time frame: year 3
Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years of follow up) in young women; HIV testing and viral load measurements are performed on the DBS samples collected during the annual survey
26 secondary outcomes
HIV testing uptake at point of test offer in women
Time frame: Baseline
HIV treatment linkage at 1 year in women
Time frame: year 1
Population-level HIV viral suppression (both sexes)
Time frame: year 1
Population-level HIV viral suppression (both sexes)
Time frame: year 3
Population-level HIV viral suppression in women
Time frame: year 1
Population-level HIV viral suppression in women
Time frame: year 3
Population-level HIV viral suppression in men
Time frame: year 3
Population level HIV incidence (both sexes)
Time frame: year 3
Population-level HIV-related mortality (both sexes)
Time frame: year 3
Population-level all-cause mortality (both sexes)
Time frame: year 3
Population-level HIV-related mortality in women
Time frame: year 3
Population-level HIV incidence in men
Time frame: year 3
HIV status knowledge in men and women
Time frame: year 1
HIV prevention knowledge in men and women
Time frame: year 1
HIV treatment utilization in men and women
Time frame: year 1
Reported condom use in men and women
Time frame: year 1
Tuberculosis (TB) healthcare utilization in men and women
Time frame: year 1
Diabetes Healthcare utilization in men and women
Time frame: year 1
Hypertension healthcare utilization in men and women
Time frame: year 1
Household wealth (household assets)
Time frame: year 3
Household wealth (food security)
Time frame: year 3
Partnership patterns in men and women
Time frame: year 1
Retention in HIV care in men and women
Time frame: year 1
Retention in HIV care in men and women
Time frame: year 3
Patient viral suppression in men and women
Time frame: year 1
Patient viral suppression in men and women
Time frame: year 3
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2018.
- Derived from this study: PubMed 42446180Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Barnighausen TW, Tanser F. Evaluating the impact of conditional micro-incentives on linkage to HIV care in rural South Africa: results from the Home-Based Intervention to Test and Start (HITS) trial. Health Policy Plan. 2026 Oct 19;41(9):1527-1542. doi: 10.1093/heapol/czag088.
- Derived from this study: PubMed 39259239Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Blandford A, Barnighausen T, Tanser F. Effect of a Male-Targeted Digital Decision Support Application Aimed at Increasing Linkage to HIV Care Among Men: Findings from the HITS Cluster Randomized Clinical Trial in Rural South Africa. AIDS Behav. 2025 Jan;29(1):1-12. doi: 10.1007/s10461-024-04465-1. Epub 2024 Sep 11.
- Derived from this study: PubMed 38562873Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Barnighausen T, Tanser F. The impact of a conditional financial incentive on linkage to HIV care: Findings from the HITS cluster randomized clinical trial in rural South Africa. medRxiv [Preprint]. 2024 Mar 18:2024.03.15.24304278. doi: 10.1101/2024.03.15.24304278.
- Derived from this study: PubMed 38562824Kim HY, Inghels M, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Gareta D, Yapa HM, Zuma T, Dobra A, Blandford A, Barnighausen T, Tanser F. Effect of a male-targeted digital decision support application aimed at increasing linkage to HIV care among men: Findings from the HITS cluster randomized clinical trial in rural South Africa. medRxiv [Preprint]. 2024 Mar 18:2024.03.15.24304373. doi: 10.1101/2024.03.15.24304373.
- Derived from this study: PubMed 37598389Makofane K, Kim HY, Tchetgen Tchetgen E, Bassett MT, Berkman L, Adeagbo O, McGrath N, Seeley J, Shahmanesh M, Yapa HM, Herbst K, Tanser F, Barnighausen T. Impact of family networks on uptake of health interventions: evidence from a community-randomized control trial aimed at increasing HIV testing in South Africa. J Int AIDS Soc. 2023 Aug;26(8):e26142. doi: 10.1002/jia2.26142.
- Derived from this study: PubMed 33586911Tanser FC, Kim HY, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P, Wyke S, McGrath N, Adeagbo O, Sartorius B, Yapa HM, Zuma T, Zeitlin A, Blandford A, Dobra A, Barnighausen T. Home-Based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa. J Int AIDS Soc. 2021 Feb;24(2):e25665. doi: 10.1002/jia2.25665.
- Individual participant dataSharing planned: Undecided
Related trials for HIV
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
RecruitingObservational study
Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
HIV
RecruitingPhase 1
Dasatinib for HIV-1 Reservoir Reduction
HIV Infections
RecruitingObservational study
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
HIV
RecruitingPhase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Human Immunodeficiency Virus (HIV) Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Frank Tanser, PhD principal investigator
Africa Health Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing micro-incentive, EPIC-HIV and micro-incentive and EPIC-HIV in people with HIV and HIV Testing, run by Africa Health Research Institute at 1 site in South Africa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sashin Harilall (0312604113 ext. 4113, sharilall@ahri.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIV testing uptake at point of test offer in men (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03757104, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2018.